Roche to buy InterMune for $8.3B

Roche, a Swiss pharmaceutical company, plans to acquire Brisbane, Calif.-based InterMune, a biotech firm, for $8.3 billion, according to a Wall Street Journal report.

Advertisement

Roche largely focuses on cancer and autoimmune-focused diagnostics and treatments. This acquisition will expand Roche’s offering to include InterMune’s respiratory offerings.

More articles on acquisitions:

Cleveland Clinic finalizes Akron General minority ownership deal
Duke LifePoint, Conemaugh Health reach definitive acquisition agreement
Allergan, Salix in potential merger talks

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.